CLOs on the Move

Fate Therapeutics

www.fatetherapeutics.com

 
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Mérieux NutriSciences

Mérieux NutriSciences is a service company headquartered in Chicago.

BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.

Molecular Express

Molecular Express is a Rancho Dominguez, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Instrumentation Laboratories

Instrumentation Laboratories is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.